Page last updated: 2024-11-06

vasicine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

vasicine: RN given refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID667496
CHEMBL ID2163791
SCHEMBL ID2610722
MeSH IDM0072151

Synonyms (35)

Synonym
vasicin [german]
pyrrolo(2,1-b)quinazolin-3-ol, 1,2,3,9-tetrahydro-
(r)-1,2,3,9-tetrahydropyrrolo(2,1-b)quinazolin-3-ol
einecs 228-180-8
vasicine
peganine
6159-55-3
(3s)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol
(-)-linarine
unii-6c2zbi733p
(-)-peganine
peganin
l-vasacine
6c2zbi733p ,
(-)-vasicine
l-peganine
vasicin
chembl2163791 ,
bdbm50396012
S5850
l-vasicine
pyrrolo(2,1-b)quinazolin-3-ol, 1,2,3,9-tetrahydro-, (3s)-
vasicine [mi]
4-amino-3-chlorobenzenesulfonylfluoride
SCHEMBL2610722
AC-35070
vasicine, analytical standard
CS-0016391
HY-N1103
AKOS032948347
FS-8877
pyrrolo[2,1-b]quinazolin-3-ol, 1,2,3,9-tetrahydro-, (3s)-
Q27264469
(3s)-1h,2h,3h,9h-pyrrolo[2,1-b]quinazolin-3-ol
DTXSID601024261

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The chromatographic fingerprints combined with PCA, HCA and LDA could distinguish the seeds of the different species of Peganum investigated."( HPLC fingerprints combined with principal component analysis, hierarchical cluster analysis and linear discriminant analysis for the classification and differentiation of Peganum sp. indigenous to China.
Bligh, SW; Cheng, XM; Wang, CH; Wang, ZT; Yang, T; Zhao, T,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The results suggest that these acrids have the capacity to increase the bioavailability of certain drugs."( Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs.
Atal, CK; Rao, PG; Zutshi, U, 1981
)
0.26
"The oral bioavailability of vasicine (1) was investigated in hard gelatin capsules of lyophilized Vasa Swaras (aqueous extract of Adhatoda vasica Nees."( Formulation and pharmacokinetic evaluation of hard gelatin capsule encapsulating lyophilized Vasa Swaras for improved stability and oral bioavailability of vasicine.
Anandjiwala, S; Dash, RP; Nivsarkar, M; Vyas, T, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Cumulative dose-response study with acetylcholine and histamine indicated for its non-specific direct effect on smooth muscles."( Synthesis and bronchodilator activity of new quinazolin derivative.
Bhagat, A; Dhar, KL; Gupta, BD; Gupta, OP; Qazi, GN; Satti, NK; Singh, GD; Suri, KA; Suri, OP; Youssouf, MS; Zabeer, A, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)3.13000.00001.559910.0000AID697830
CholinesteraseEquus caballus (horse)IC50 (µMol)2.53000.00002.22149.4000AID697829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID697831Inhibition of electric eel AChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1368921Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Cytotoxic quinazoline alkaloids from the seeds of Peganum harmala.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1503775Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells assessed as chlamydial inhibition at 50 uM after 70 hrs by fluorescent microscopic analysis2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID1368923Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability by MTT assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Cytotoxic quinazoline alkaloids from the seeds of Peganum harmala.
AID697830Inhibition of human BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697829Inhibition of horse BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1368922Cytotoxicity against human HL60 cells assessed as reduction in cell viability by trypan blue method2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Cytotoxic quinazoline alkaloids from the seeds of Peganum harmala.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (22.92)18.7374
1990's0 (0.00)18.2507
2000's6 (12.50)29.6817
2010's27 (56.25)24.3611
2020's4 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]